Genmab A/S (GMAB) stock
Close on Nov 12, 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Diluted shares
- 63M
Trading
- Previous close
- $53.87
- Open
- $52.20
- Day's range
- $51.53 – $53.03
- Volume
- 5,627,969
- Average volume (20 days)
- 6,514,015
- Beta (5 years)
- 0.74
- RSI (14 days)
- 60.2
- Volatility (1 year)
- 45.8%
- Relative volume
- 1.55×
Valuation needs the share price. It fills in once daily prices are connected and converted from DKK.
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | GMAB | S&P 500 | Difference | GMAB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +38.5% | -2.7% | +41.1 pts | ||
| 3 months | +64.7% | -1.7% | +66.4 pts | ||
| Year to date | +68.0% | +11.9% | +56.1 pts | ||
| 1 year | +69.8% | +12.0% | +57.8 pts | ||
| 3 years | +64.5% | +78.2% | −13.7 pts | +18.1% | +21.2% |
| 5 years | +19.0% | +73.2% | −54.2 pts | +3.5% | +11.6% |
| 10 years | +194.5% | +309.6% | −115.1 pts | +11.4% | +15.1% |
Ten years at a glance
Fiscal years 2016 to 2025, DKK
Revenue
Gross profit
Operating income
EPS, diluted
Free cash flow
Press releases
Releases Genmab A/S filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Genmab A/S
Pharmaceutical Preparations
Genmab A/S is a biotechnology company focused on developing antibody-based therapeutics for the treatment of diseases, primarily targeting cancer indications such as multiple myeloma. The company creates proprietary antibody technologies and therapies while also collaborating with pharmaceutical partners to develop, acquire, and commercialize products, including daratumumab and investigational candidates like petosemtamab and Rina-S. Its treatments are designed for healthcare systems, physicians, and patient populations requiring specialized therapies, including patients who have failed prior therapies.
Company profile, executives and historyGenmab A/S stock: common questions
What is Genmab A/S's stock price?
GMAB closed at $51.74 on Nov 12, 2026, down 3.95% on the day.
Does Genmab A/S pay a dividend?
No. Genmab A/S has not paid a cash dividend over the last twelve months.
How has GMAB stock performed over the past year?
Including dividends, GMAB returned +69.8% over the past year, against +12.0% for the S&P 500.
Who are Genmab A/S's competitors?
Companies most similar to Genmab A/S by business, industry and size include REGN, VRTX, AZN, GSK, BMY.
See a number that looks wrong?